Genomic landscape of patients in a phase II study of zanubrutinib in ibrutinib- and/or acalabrutinib-intolerant patients with B-cell malignancies

Haematologica. 2024 Jul 1;109(7):2284-2289. doi: 10.3324/haematol.2023.283861.
No abstract available

Publication types

  • Clinical Trial, Phase II
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenine* / analogs & derivatives
  • Aged
  • Aminobutyrates / adverse effects
  • Aminobutyrates / therapeutic use
  • Benzamides* / therapeutic use
  • Female
  • Genomics / methods
  • Humans
  • Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy
  • Leukemia, Lymphocytic, Chronic, B-Cell / genetics
  • Leukemia, Lymphocytic, Chronic, B-Cell / mortality
  • Male
  • Middle Aged
  • Mutation
  • Piperidines* / therapeutic use
  • Protein Kinase Inhibitors / adverse effects
  • Protein Kinase Inhibitors / therapeutic use
  • Pyrazines* / administration & dosage
  • Pyrazines* / adverse effects
  • Pyrazines* / therapeutic use
  • Pyrazoles* / administration & dosage
  • Pyrazoles* / adverse effects
  • Pyrazoles* / therapeutic use
  • Pyrimidines* / administration & dosage
  • Pyrimidines* / adverse effects
  • Pyrimidines* / therapeutic use
  • Sulfonamides / adverse effects
  • Sulfonamides / therapeutic use
  • Thiazoles / administration & dosage
  • Thiazoles / adverse effects
  • Thiazoles / therapeutic use

Substances

  • acalabrutinib
  • Adenine
  • Aminobutyrates
  • Benzamides
  • ibrutinib
  • Piperidines
  • Protein Kinase Inhibitors
  • Pyrazines
  • Pyrazoles
  • Pyrimidines
  • Sulfonamides
  • Thiazoles
  • zanubrutinib

Grants and funding

Funding: This study was sponsored by BeiGene, Ltd.